• Pomerantz LLP has announced that the U.S. District Court for the District of Massachusetts previously approved notice of a proposed US$6,500,000 class action settlement for investors who bought Amylyx Pharmaceuticals securities between November 11, 2022, and November 8, 2023, with a final approval hearing scheduled for September 10, 2026.
• The settlement process, including deadlines for claim submissions, exclusions, and objections, adds a legal and governance dimension that investors may weigh alongside Amylyx’s advancing drug pipeline.
• We’ll now examine how this proposed class action settlement interacts with Amylyx’s push toward a pivotal Phase 3 avexitide readout and potential commercialization.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Amylyx Pharmaceuticals Investment Narrative Recap

To own Amylyx today, you have to believe avexitide can become the first approved treatment for post bariatric hypoglycemia and eventually support a broader rare disease portfolio, even with no current revenue and ongoing losses. The proposed US$6,500,000 class action settlement appears relatively modest next to the company’s cash balance and R&D plans, and by itself does not materially change the key near term catalyst or the main risk around the pivotal Phase 3 LUCIDITY readout.

Against this legal backdrop, Amylyx is moving toward a pivotal Phase 3 avexitide topline readout in Q3 2026 and preparing for a potential 2027 launch. This timing keeps the LUCIDITY data and any future commercial execution in PBH at the center of the story, even as the company advances AMX0318 in PBH and AMX0114 and AMX0035 in neurodegeneration. How the trial reads out, and how payers and physicians respond if avexitide reaches the market, will likely matter far more than this settlement.

Yet compared with the promise around avexitide, the risk that PBH prescribing remains focused on nutrition based management is something investors should be aware of...

Amylyx Pharmaceuticals' narrative projects $107.8 million revenue and $23.1 million earnings by 2029. This implies an earnings increase of about $167.8 million from -$144.7 million today.

Uncover how Amylyx Pharmaceuticals' forecasts yield a $22.20 fair value, a 60% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already cautious, projecting only about US$46.5 million of revenue and US$9.3 million of earnings by 2029, and this new legal development could further shift how you and they think about the timing and risk of Amylyx’s PBH opportunity.

Explore 3 other fair value estimates on Amylyx Pharmaceuticals - why the stock might be worth less than half the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Amylyx Pharmaceuticals research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Amylyx Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amylyx Pharmaceuticals' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.